Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 13/20 | 0.57 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.47 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.47 |
| ▸ | MMP8 | P22894 | 1/20 | 0.45 |
| ▸ | MMP12 | P39900 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.43 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL892880 | 0.90 | TRPA1 (0.57) | TRPA1MMP8MMP12MMP13ALDH1A1 | |
| SCHEMBL894116 | 0.88 | TRPA1 (0.49) | TRPA1HCRTR1HCRTR2MMP8MMP12 | |
| SCHEMBL893916 | 0.88 | TRPA1 (0.55) | TRPA1SCN9A | |
| SCHEMBL893809 | 0.86 | TRPA1 (0.53) | TRPA1SCN9A | |
| SCHEMBL17136546 | 0.85 | TRPA1 (0.54) | TRPA1HCRTR1HCRTR2MMP8MMP12 | |
| SCHEMBL893831 | 0.85 | TRPA1 (0.78) | TRPA1 | |
| SCHEMBL17136379 | 0.84 | TRPA1 (0.52) | TRPA1HCRTR1HCRTR2MMP8MMP12 | |
| SCHEMBL16210354 | 0.84 | TRPA1 (0.49) | TRPA1HCRTR1HCRTR2MMP8MMP12 | |
| SCHEMBL17136552 | 0.84 | HCRTR1 (0.55) | TRPA1HCRTR1HCRTR2MMP8MMP12 | |
| SCHEMBL16210090 | 0.84 | TRPA1 (0.48) | TRPA1HCRTR1HCRTR2MMP8MMP12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120083474-A1 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-05 | — | — | US | claimed |
| US-20120083474-A1 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-05 | — | — | US | disclosed |
| US-20120083474-A1 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-05 | — | — | US | disclosed |
| WO-2010141805-A1 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083474-A1 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 | TRPA1, TRPV1, TRPV2 | TRPA1 1/4885HCRTR1 168/4885HCRTR2 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.